Content :
Thrombosis
Products organised per phase
| Phase |
Product |
Product |
Product |
Product |
|
Approved /
Launched /
LCM
|
LOVENOX®
enoxaparin
DVT prophylaxis (hip/knee replacement,
abdominal surgery, medically ill);
DVT treatment with/without PE,
UA/non-Q wave MI; AMI, US/EU;
DVT prophylaxis (hip/knee replacement), Japan
|
PLAVIX®
clopidogrel
Unstable angina; Prevention
of thrombotic events after MI,
stroke and PAD; Acute myocardial
infarction; Stent/ACS, EU;
300 mg tablet, US; ACS, Japan
|
- |
- |
| Submitted |
PLAVIX®
clopidogrel
300 mg tablet, EU;
Combo ASA, EU/US
|
- |
- |
- |
| Phase III |
idraparinux
Long-acting pentasaccharide;
indirect Xa inhibitor
Long term treatment DVT/PE;
Atrial fibrillation
|
idrabiotaparinux
Biotinylated long acting pentasaccharide;
Indirect Xa inhibitor
Long term treatment DVT/PE;
Atrial fibrillation
|
LOVENOX®
enoxaparin
Pen; abdominal surgery,
Japan
|
PLAVIX®
clopidogrel
Prevention in "at risk" patients;
AF; Pediatric extension; ACS high
loading dose
|
| Phase IIb |
otamixaban
(XRP0673)
Direct Xa inhibitor
ACS
|
AVE5026
Indirect Xa/IIa inhibitor
VTE prevention
|
- |
- |
| Phase IIa |
- |
- |
- |
- |
| Phase I |
- |
- |
- |
- |
| Preclinical |
SAR104772
TAFIa inhibitor
Thrombo-embolic diseases
|
SSR128428
Long-acting hexadecasaccharide;
indirect Xa/IIa inhibitor
Thrombo-embolic diseases
|
- |
- |
R&D portfolio presented on February 12, 2008
|
